Lexicon Pharmaceuticals is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 285 staff and has a trailing 12-month revenue of around $3.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.61 |
|---|---|
| 52-week range | $0.92 - $3.73 |
| 50-day moving average | $1.84 |
| 200-day moving average | $1.82 |
| Wall St. target price | $6.20 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.61 from 2024-09-03
| 1 week (2024-08-29) | -10.56% |
|---|---|
| 1 month (2024-08-05) | 6.27% |
| 3 months (2024-06-05) | -17.01% |
| 6 months (2024-03-05) | -28.44% |
| 1 year (2023-09-05) | -1.83% |
|---|---|
| 2 years (2022-09-02) | -40.81% |
| 3 years (2021-09-03) | 4.97 |
| 5 years (2019-09-05) | 24.81% |
| Revenue TTM | $3.6 million |
|---|---|
| Gross profit TTM | $-52,677,000 |
| Return on assets TTM | -35.69% |
| Return on equity TTM | -94.81% |
| Profit margin | 0% |
| Book value | $0.66 |
| Market Capitalization | $625.4 million |
TTM: trailing 12 months
We're not expecting Lexicon Pharmaceuticals to pay a dividend over the next 12 months.
Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 20 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.
Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $0.92 up to $3.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.357. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. .
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
A deep dive into the highlights and limitations of Frec.
Compare pros, cons, research tools and reviews for these two trading platforms.
What you need to know about investing in the leading indicator for the overall US stock market.
An online REIT with low fees, consistent dividends and a stable portfolio, but a brief track record.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.